Dr. Raj Pruthi

Raj Pruthi is an accomplished physician, surgeon and clinical scientist with an extensive career in academic medicine and industry and long publication history. He is Chief Medical Officer at Relmada Therapeutics, Inc. In his current role he is leading the development of the NDV-011 program as it enters the stage of a registrational therapeutic trial for bladder cancer and as part of its pathway to FDA approval. The program is currently in a phase 2 open-label study with plans for a multinational phase 3 study set to start in first half of 2026. Dr. Pruthi is involved in all aspects of KOL engagement, site recruitment and activation, patient inclusion (and exclusion) endpoint assessments, and all aspects related to execution for this registrational study. In addition, part of Dr. Pruthi’s role is external engagement with KOLs, patient advocacy organizations, and with investors addressing unmet needs, scientific rationale, study execution, cash runways, and regulatory filings (FDA, EU) and pre-commercialization efforts.

At Relmada, Dr. Pruthi is overseeing the clinical development of NDV-01. Prior to joining Relmada, Dr. Pruthi was Chief Medical Officer at enGene Holdings Inc., where he led a global team in the development of a registrational therapeutic trial for bladder cancer. Prior to that, he was the Global Medical Affairs Leader, Bladder Cancer and Senior Medical Director, Oncology (Global – Prostate and Bladder Cancer) at Johnson and Johnson Innovative Medicine.

Dr. Pruthi holds multiple leadership roles within the urology community. He is the Chair of the Advisory Council for Urology of the American College of Surgeons and serves on its Board of Governors. He is currently an Adjunct Professor in the Department of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell and Professor, Department of Health System Sciences, Thomas F. Frist, Jr. College of Medicineat Belmont University. Previously, he served as Professor and Chair of the Department of Urology at the University of California at San Francisco and at the University of North Carolina, Chapel Hill.

Dr. Pruthi is a former member of the American Board of Urology/American Urological Association Examination Committee and is Past-President for the Society of Academic Urology. He served on the Guidelines Committee and helped to develop the AUA Guidelines on the Management of NMIBC, and also served on the Bladder Cancer Guidelines Committee of the International Consultation on Urological Diseases. Dr. Pruthi graduated from Duke University School of Medicine and completed his residency and post-graduate training in Urologic Surgery at Stanford University. He also holds a Master of Health Administration from the University of North Carolina at Chapel Hill.